Cellectis S.A. (NASDAQ:CLLS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Cellectis S.A. (NASDAQ:CLLS) has been given an average recommendation of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $7.00.

CLLS has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellectis in a research note on Friday, July 17th. Barclays assumed coverage on Cellectis in a research note on Thursday, May 28th. They issued an “overweight” rating and a $9.00 target price for the company. Finally, Citizens Jmp restated a “market outperform” rating and issued a $8.00 price target on shares of Cellectis in a report on Tuesday, April 14th.

Hedge Funds Weigh In On Cellectis

Several institutional investors and hedge funds have recently modified their holdings of CLLS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Cellectis during the 4th quarter worth approximately $15,385,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellectis by 228.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company’s stock valued at $5,856,000 after buying an additional 3,284,409 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after buying an additional 168,038 shares during the period. Citadel Advisors LLC acquired a new position in shares of Cellectis in the third quarter valued at approximately $633,000. Finally, Millennium Management LLC increased its position in shares of Cellectis by 61.9% during the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 22,080 shares in the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Trading Down 2.8%

CLLS opened at $2.76 on Tuesday. The firm’s fifty day moving average is $2.94 and its two-hundred day moving average is $3.46. The company has a debt-to-equity ratio of 1.61, a quick ratio of 1.37 and a current ratio of 1.37. The firm has a market cap of $276.94 million, a PE ratio of -4.25 and a beta of 2.91. Cellectis has a twelve month low of $2.35 and a twelve month high of $5.48.

Cellectis (NASDAQ:CLLS) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.04. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%. The company had revenue of $6.90 million during the quarter, compared to analyst estimates of $11.05 million.

Cellectis Company Profile

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.